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Key Points
Question
What were ocular outcomes at 12 months’ corrected age for eyes that received a dose of 0.625 mg to 0.031
mg of bevacizumab for type 1 retinopathy of prematurity?
Findings
In this cohort study of 46 infants (87 eyes), 12 eyes had myopia greater than −5.00 D spherical equivalent,
and 2 eyes had hyperopia greater than 5.00 D spherical equivalent. Abnormalities of the cornea, lens, or
anterior segment were reported in 1 eye, 3 eyes, and 3 eyes, respectively.
Meaning




Lower bevacizumab dosages are being used for type 1 retinopathy of prematurity, but there are limited data
on long-term ocular outcomes with lower doses.
Objective
To evaluate ocular outcomes at 12 months’ corrected age for eyes that received a dose of 0.625 mg, 0.25
mg, 0.125 mg, 0.063 mg, or 0.031 mg of bevacizumab for type 1 retinopathy of prematurity.
Design, Setting, and Participants
This prospective cohort study used a masked, multicenter, phase 1 dose de-escalation study design and was
conducted from April 2016 to October 2017. Study eyes were treated with a dose of 0.25, 0.125, 0.063, or
0.031 mg of bevacizumab; fellow eyes were treated with a dosage 1 level higher than the study eye.
Additional treatment after 4 weeks was at investigator discretion. Data analysis occurred from November
2018 to March 2019.
Interventions
Intravitreous bevacizumab injections of 0.625 mg to 0.031 mg.
Main Outcomes and Measures
Visual fixation, amblyopia, alignment, nystagmus, cycloplegic refraction, and ocular examinations were
assessed at 12 months’ corrected age as preplanned secondary outcomes. The primary outcome 4 weeks
after treatment and secondary outcomes after 6 months’ corrected age have been previously reported.
Results
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Forty-six of 61 infants (75%) had a 12-month follow-up examination (46 study eyes and 43 fellow eyes;
median [interquartile range] birth weight, 650 [590-760] g). Of 87 eyes with a cycloplegic refraction, 12
(14% [95% CI, 7%-27%]) had myopia of more than −5.00 D spherical equivalent; 2 (2%; [95% CI,
0%-8%]) had hyperopia greater than 5.00 D spherical equivalent; and 5 infants (11% [95% CI, 4%-24%])
had anisometropia greater than 1.50 D spherical equivalent. Abnormalities of the cornea, lens, or anterior
segment were reported in 1 eye (1% [95% CI, 0%-6%]), 3 eyes (3% [95% CI, 1%-10%]), and 3 eyes (3%
[95% CI, 1%-10%]), respectively. Optic nerve atrophy was identified in 11 eyes (13% [95% CI, 6%-26%]),
and 1 eye (1% [95% CI, 0%-6%]) had total retinal detachment. Strabismus was reported in 13 infants (30%
[95% CI, 17%-45%]), manifest nystagmus in 7 infants (15% [95% CI, 6%-29%]), and amblyopia in 3
infants (7% [95% CI, 1%-18%]). Overall, 98% of infants had central fixation in each eye (44 of 45 eyes).
Conclusions and Relevance
In this study of low-dose bevacizumab, the secondary outcomes of high myopia, strabismus, retinal
detachment, nystagmus, and other ocular abnormalities at 1 year were consistent with rates reported in




Retinopathy of prematurity (ROP) is an important cause of childhood vision loss in the United States.
Historically, severe ROP has been primarily treated with laser photocoagulation of the peripheral avascular
retina.  More recently, intravitreal bevacizumab (IVB) has been used increasingly in the United States
and internationally as treatment for severe type 1 ROP, in particular for aggressive posterior ROP.
Lower dosages are being used to treat type 1 ROP, but there are limited data on long-term ocular outcomes.
The Pediatric Eye Disease Investigator Group (PEDIG) is conducting a phase 1 trial of bevacizumab
treatment for severe retinopathy of prematurity (the ROP1 study) to evaluate the effectiveness of dosages of
bevacizumab that are lower than those typically used to treat ROP. Details of drug dilution and injection,
4-week outcomes, and any additional retreatments for ROP were reported previously.  In brief, 61 infants
with ROP received 0.25 mg, 0.125 mg, 0.063 mg, or 0.031 mg in the study eye, and the study found that
the lowest dosage of 0.031 mg was effective after 4 weeks.  Each dosage was planned to be used in up to
14 infants to ensure that at least 10 infants had 4-week outcomes. After 6 months’ corrected age, 25 infants
(41% [95% CI, 29%-54%]) received additional treatment: 3 infants (5% [95% CI, 1%-14%]) for early
failure (within 4 weeks), 11 infants (18% [95% CI, 9%-30%]) for late recurrence of ROP (after 4 weeks),
and 11 infants (18% [95% CI, 9%-30%]) for persistent avascular retina.  The study continues to evaluate
dosage levels of 0.016 mg, 0.008 mg, 0.004 mg, 0.002 mg, and 0.001 mg, and those results are pending.
The objectives of this article are to report ocular findings at 12-months’ corrected age for the 61 infants
treated with the first 4 lower dosages of IVB (0.25 mg, 0.125 mg, 0.063 mg, and 0.031 mg) and to explore
whether there are any associations between ocular findings and total dosage of IVB received at the eye or
infant level. Ocular and neurological findings for a subset of infants whose parents consented for an
examination at 24 months’ corrected age are pending completion and will be reported separately.
Methods
The cohort for this article was limited to the 61 patients treated in the study eye with the first 4 dose levels
in the ROP1 PEDIG phase 1 study (0.25 mg, 0.125 mg, 0.063 mg, and 0.031 mg).  The study was
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A parent or guardian of each study infant gave written informed consent. The study is listed on
ClinicalTrials.gov (NCT02390531). The complete study protocol is available on the PEDIG website
(http://www.pedig.net). Additional details are available in the Trial Protocol in Supplement 1.
Treatment was initiated by the investigator when 1 or both eyes reached type 1 severity, defined as any
stage ROP in zone I with plus disease, stage 2 or 3 ROP in zone II with plus disease, or stage 3 ROP in
zone I without plus disease.  One eye (called the study eye) of 61 infants received the study-specified
dosage of IVB: 11 eyes received 0.25 mg, 16 eyes received 0.125 mg, 24 eyes received 0.063 mg, and 10
eyes received 0.031 mg. Fifty-seven nonstudy fellow eyes received IVB at a dosage that was 1 level higher
than the study eye (ie, the last dosage found to be effective in the study; eg, 0.063 mg in the fellow eye
when 0.031 mg was injected into the study eye). The remaining 4 fellow eyes did not have ROP severe
enough to warrant treatment.
Infants were examined at 1 day (and 4 days if needed) and 1, 2, 3, and 4 weeks’ postinjection in the study
eye. Beginning 4 weeks after the initial bevacizumab injection, any additional treatment was at investigator
discretion. After 6 months’ corrected age, medical records were reviewed to collect data on ROP
recurrences, additional treatments, timing of and indications for treatment, and retinal structural outcomes.
After 4 weeks, follow-up examinations and additional treatments were at investigator discretion, with the
exception of a study-mandated examination completed at 12 months’ (±2 weeks’) corrected age,
subsequently referred to as the 12-month examination. Preplanned secondary outcomes of visual fixation,
amblyopia, ocular alignment, nystagmus, cycloplegic refraction, and anterior and posterior segment
examinations were assessed at the 12-month examination.
Statistical Analysis
For those who completed the 12-month examination, the proportion of infants with each clinical outcome
and 95% CIs were tabulated at the eye and infant level. For eye-level outcomes, to account for the
correlation between eyes of infants who contribute both eyes to tabulations of ocular characteristics, a
logistic regression model was used to compute the log odds of having the ocular characteristic and CIs for
those log odds. The inverse logit function was used to calculate the proportion of eyes with the ocular
characteristic and the corresponding 95% CI. For infant-level outcomes, binomial proportions were
calculated for each ocular outcome along with corresponding exact 95% CIs.
The total dosage of bevacizumab administered per infant in the study eye (and fellow eye if applicable) and
the total dosage of bevacizumab administered per eye prior to the 12-month examination was calculated for
each infant. This total bevacizumab dosage included the initial injection into the study eye or fellow eye
and any repeated injections as treatment for ROP prior to the 12-month examination. Exploratory analyses
were performed to evaluate whether there was any association between the total dosage of bevacizumab
received (in either the infant or the eye, depending on whether the outcome was eye level or infant level)
and each 12-month outcome. For continuous 12-month outcomes, a linear mixed model adjusting for the
correlation between eyes (for spherical equivalent of the cycloplegic refraction) or linear regression model
(for anisometropia) was used to evaluate the association between total dose and each continuous 12-month
outcome. For categorical 12-month outcomes (percentages of the study population with hyperopic spherical
equivalent >5.00 diopters [D], myopic spherical equivalent <−5.00 D, an abnormal ocular examination
finding of the cornea or lens, optic nerve atrophy, macular ectopia, retinal detachment, retinal fold, constant
strabismus at distance or near, manifest nystagmus, and amblyopia), a generalized linear model adjusting
for the correlation between eyes (if the variable was at an eye level) or logistic regression (if on a
participant level) was used to evaluate the association between total dosage and each binary outcome.
Given the secondary and exploratory nature of these analyses, P values of .05 or less were considered
suggestive of but not definitive for associations that may merit further study.
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Additional exploratory analyses evaluated whether there was any association between spherical equivalent
cycloplegic refractive error at the 12-month examination and location of ROP in zone I or zone II at
baseline and any association between spherical equivalent cycloplegic refractive error at the 12-month
examination and prior laser treatment or no laser treatment after the initial bevacizumab injection. Analyses
were conducted using SAS version 9.4 (SAS Inc). More details are available in the Statistical Analysis Plan
in Supplement 2.
Results
Forty-six of 61 infants (75%) completed the 12-month examination. Infants initially treated in the study eye
with lower dosages of bevacizumab were less likely to return for the 12-month examination than infants
initially treated in the study eye with higher dosages of bevacizumab (11 of 11 infants initially treated with
0.25 mg [100%], 13 of 16 infants treated with 0.125 mg [81%], 16 of 24 infants treated with 0.063 mg
[67%], and 6 of 10 infants treated with 0.031 mg [60%]; Table 1). Characteristics of the 46 infants who
completed the 12-month examination, as well as the 15 infants who did not complete the 12-month
examination (of whom 6 had died prior to 12 months from causes not associated with the study drug) are
summarized in Table 1. The 46 infants who completed the 12-month examination tended to have higher
birth weights than those who did not (median [interquartile range (IQR)], 650 [590-760] g vs 610
[545-790] g) and were more likely to have a preexisting condition associated with neurodevelopment (22
[48%] vs 4 [27%]) than those who did not complete the 12-month examination. The 46 infants with 12-
month outcomes had 89 eyes (46 study eyes and 43 fellow eyes) treated with bevacizumab.
Cycloplegic Refractive Error at 12 Months
Cycloplegic refractive error was measured by retinoscopy in 87 eyes, of which 12 eyes (14% [95% CI,
7%-27%]) had myopia greater than −5.00 D spherical equivalent (SE) and 2 eyes (2% [95% CI, 0%-8%])
had hyperopia greater than 5.00 D SE. The mean (SD) SE refractive error were −0.82 (4.56) D; the median
(IQR) SE was 0 (−1.88 to 1.25) D (Table 2). Five infants (11% [95% CI, 4%-24%]) were found to have
anisometropia greater than 1.50 D SE (Table 3). The mean (SD) SE cycloplegic refractive error of 38 eyes
with a zone I location at baseline was −0.76 (5.25) D, and the median (IQR) was −0.50 (−2.38 to 1.00) D vs
a mean (SD) of −0.87 (4.00) D and a median (IQR) of 0.38 (−1.50 to 1.50) D in 49 eyes with a zone II
location at baseline (adjusted difference in means, −0.03 D [95% CI, −13.38 to 13.32 D]).
Laser treatment to the avascular retina after initial bevacizumab was performed in 27 eyes prior to the 12-
month examination for recurrent ROP (10 eyes) or persistent avascular retina (17 eyes), at a median of 24
(range, 1-45) weeks’ corrected age or 64 (IQR, 41-85) weeks’ postmenstrual age. Additional details and
indications for additional treatments were previously reported.  The mean (SD) SE cycloplegic refractive
error of the 25 eyes receiving laser treatment after initial bevacizumab was −0.71 (5.77) D and the median
(IQR) was −0.75 (−2.38 to 0.75) D vs a mean (SD) of −0.87 (4.02) D and a median (IQR) of 0.25 (−1.50 to
1.50) D in 62 eyes not receiving laser treatment (adjusted difference in means, −0.18 D [95% CI, −14.26 to
13.91 D]).
Ocular Examination at 12 Months
Abnormalities of the cornea, lens, or other anterior segment were reported in 1 eye (1% [95% CI, 0%-6%]),
3 eyes (3% [95% CI, 1%-10%]), and 3 eyes (3% [95% CI, 1%-10%]), respectively (Table 2). Optic nerve
atrophy was identified in 11 eyes (13% [95% CI, 6%-26%]); no cases of macular ectopia were reported,
and 1 eye (1% [95% CI, 0%-6%]) had a total retinal detachment attributable to severe recurrent disease 10
weeks after initial injection (Table 2). The extent of peripheral retinal vascularization could be determined
for 72 of 89 eyes (81%), of which 22 eyes (31% [95% CI, 20%-43%]) were not zone III or fully
vascularized (Table 2).
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Constant or intermittent strabismus at distance or near fixation was reported in 13 infants (30% [95% CI,
17%-45%]), while manifest nystagmus was reported in 7 infants (15% [95% CI, 6%-29%]), and amblyopia
in 3 infants (7% [95% CI, 1%-18%]) (Table 3). Overall, 98% of infants had central fixation in each eye (44
of 45 eyes), and 36 of 45 eyes (80%) had central, steady, and maintained fixation in each eye.
Association With Total Dosage
Following the initial injection, 14 eyes received additional treatment with IVB prior to the 12-month ocular
examination (0.125 mg for 1 eye, 0.5 mg for 4 eyes, and 0.625 mg for 9 eyes) at a median of 1 weeks’
corrected age (range, −6 to 5 weeks’ corrected age) or 41 (IQR, 34-45) weeks’ postmenstrual age. There
were no associations identified between any ocular examination findings, and the total dose of
bevacizumab received prior to the 12-month examination. All P values for an association were .10 or
greater (Tables 2 and 3).
Discussion
Among the 46 infants treated with dosages of intravitreal bevacizumab ranging from 0.25 to 0.031 mg who
later completed a 12-months’ corrected-age outcome examination, the rates of high myopia, strabismus,
nystagmus, retinal detachment, and other ocular findings were low and consistent with rates reported for
infants treated with higher dosages of bevacizumab and laser ablative treatment. Chen et al  treated 57 eyes
with 0.625 mg (0.025 mL) of bevacizumab and follow-up laser treatment if needed and reported that 9 eyes
(16%) had high myopia of −5.00 D or greater when the patients were 2 years of age, which was similar to
the rate of 14% observed in this study. Harder et al  found the prevalence of high myopia to be 9% in 23
eyes treated with either 0.375 mg or 0.625 mg of bevacizumab, which was also similar to the rate of 14%
observed in this study. Among 22 eyes treated with 0.625 mg of IVB, Hwang et al  reported a mean SE
refractive error of −3.7 D for eyes with ROP in zone I vs 0.6 D for eyes with ROP in zone II; these were
contrary to our findings of no difference in SE refractive error between zone I and II locations. Our results
were based on the mean (−0.76 D for zone I vs −0.87 D for zone II) and might be subject to the changes
caused by small numbers and outliers. Our results using the median refractions are consistent with those of
Hwang et al  with respect to those with a zone I location being more myopic (medians: −0.50 D for eyes
with ROP in zone I; 0.38 D for eyes with ROP in zone II).
VanderVeen et al  reported rates of 30% with strabismus after laser ablative treatment, similar to the rate
of 30% in infants receiving IVB in this study. In the Early Treatment for Retinopathy of Prematurity Study
(ETROP) study, which used laser ablation, Wheeler et al  reported a similar rate of nystagmus (17%), a
lower rate of strabismus (16%), and a higher rate of high myopia (32%) compared with the infants in this
study, who received IVB. A report by Good et al  that also used the ETROP study data reported similar
rates of optic atrophy (9%), cataract (5%), macular ectopia (6%), retinal fold (3%), and retinal detachment
(3%) at age 6 years in eyes treated with lasers for ROP. Fixation behavior in eyes treated with lasers was
reported as uncentral eccentric fixation in 12% of participants and unsteady fixation in 22% of participants,
which was consistent with the rates observed in the infants in this study, who were treated with IVB.
Limitations
This study has several limitations. First, the sample size was small overall and in each dosage-defined
subgroup, limiting our ability to evaluate the frequency of outcomes with high precision as well as whether
outcomes differed between total dosage levels of bevacizumab. This study also did not use fluorescein
angiography to document the peripheral vasculature. Another limitation is that infants treated with lower
dosages in the study eye were more likely not to have completed the 12-months’ corrected-age
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association between the total injected dosage of bevacizumab and clinical and/or ocular findings, and it
potentially biased results, because those infants not completing the 12-month examination differed from
those completing the examination. The current observed 12-month ocular findings are generalizable only to
those treated with low dosages of 0.25 mg, 0.125 mg, 0.063 mg, and 0.031 mg. Because study eyes could
not be treated with 0.625 mg and fellow eyes could not be treated with 0.031 mg per the study protocol, the
total number of eyes treated with those dosages was particularly small. In addition, almost half of treated
eyes received retreatment with lasers (27 eyes) or additional injections (14 eyes) prior to the 12-month
examination. In addition, we had no control group because this was a phase 1 study.
Conclusions
In conclusion, in this long-term study of low-dose bevacizumab for type I ROP, the rates of high myopia,
strabismus, retinal detachment, nystagmus, and other ocular abnormalities at 1 year (corrected age) were
consistent with rates reported for higher dosages of bevacizumab and laser ablative treatment. A larger
future study with a randomized comparison group not receiving anti–vascular endothelial growth factor
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Table 1.






Female 20 (43) 6 (40)
Race/ethnicity
White 23 (50) 8 (53)
Black/African American 8 (17) 3 (20)
Hispanic/Latino 8 (17) 2 (13)
Asian/American Indian/Alaska Native 2 (4) 1 (7)
>1 Race 3 (7) 1 (7)
Unknown/not reported 2 (4) 0
Gestational age, wk
Mean (SD) 24.9 (1.7) 24.8 (1.4)
Median (IQR) 24.9 (23.7-25.9) 24.1 (23.9-26.0)
Initial intravitreal bevacizumab dose in study eye,
mg
0.25 11 (24) 0
0.125 13 (28) 3 (20)
0.0625 16 (35) 8 (53)
0.03125 6 (13) 4 (27)
Stage of retinopathy of prematurity in study eye at
baseline
Stage 2 or 3 in zone II with plus disease 26 (57) 8 (53)
Stage 3 in zone I without plus disease 5 (11) 3 (20)
Any stage in zone I with plus disease 15 (33) 4 (27)
Birth weight, g
Mean (SD) 727 (336) 656 (162)
Median (IQR) 650 (590-760) 610 (545-790)
Open in a separate window
Abbreviations: IQR, interquartile range; NA, not applicable.
Preexisting conditions that could affect neurodevelopmental milestones were included, such as intraventricular
hemorrhage, periventricular leukomalacia, and hydrocephalus.
a
Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Be... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865236/?report=printable
10 of 14 11/19/2021, 1:31 PM
Table 2.
Clinical Testing and Ocular Examination Findings at the 12-Month Outcome Examination
(Study and Fellow Eyes Combined)
Characteristic Eyes, No. (%) P
ValueOverall Total Dosage of Bevacizumab Injected Into Eye Prior to 12
mo, mg
≤0.0625 0.125 0.25 >0.25
Eyes, No. 89 24 24 25 16 NA
Cycloplegic refraction
(spherical equivalent)
Not done 2 (2) 0 0 1 (4) 1 (6)
NA
<−5.00 D 12 (13) 3 (13) 3 (13) 3 (12) 3 (19)
−5.00 D to ≤−1.00 D 17 (19) 6 (25) 3 (13) 3 (12) 5 (31)
>−1.00 D to <1.00 D 30 (34) 10 (42) 8 (33) 8 (32) 4 (25)
≥1.00 D to ≤5.00 D 26 (29) 5 (21) 9 (38) 9 (36) 3 (19)
>5.00 D 2 (2) 0 1 (4) 1 (4) 0






































No. (%) [95% CI]
Abnormal
Anterior segment 3 (3) [1-10] 1 (4) [0-21] 1 (4) [0-21] 1 (4) [0-20] 0 (0) [0-21] .99
Cornea 1 (1) [0-6] 0 (0) [0-14] 0 (0) [0-14] 1 (4) [0-20] 0 (0) [0-21] .99
Lens 3 (3) [1-10] 0 (0) [0-14] 1 (4) [0-21] 1 (4) [0-20] 1 (6) [0-30] .87
Optic nerve atrophy 11 (12) [6-21] 3 (13) [3-32] 3 (13) [3-32] 4 (16) [5-36] 1 (6) [0-30] .49
Macular ectopia 0 (0) [0-4] 0 (0) [0-14] 0 (0) [0-14] 0 (0) [0-14] 0 (0) [0-21] NA
Open in a separate window
Abbreviations: IQR, interquartile range; NA, not applicable.
If there were 0 events, P values are not reported; if data are presented as both a continuous and categorical outcome,
then a P value is only presented for the outcome as a continuous measure.
Number of eyes treated initially with bevacizumab examined at the 12-month examination. Total dosages were
grouped into 4 groups.
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association between the continuous factors and total dosage as a categorical factor.
Seven eyes of 4 infants; 1 infant had a smaller corneal diameter than normal in the study eye, with inferior and
superior anterior synechiae after receiving subsequent laser treatment; 1 infant had corectopia in both eyes; 1 infant
had bilateral aphakia after receiving subsequent laser treatment; and 1 infant had a tiny corneal opacity in the fellow
eye.
Since there is a limited number of outcomes, the P value is from a Fisher exact test without accounting for any
correlation between eyes for an association between the binary outcome and total dose as categorical factor.
The P value from logistic regression was presented after accounting for any correlation between eyes for an
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Table 3.
Clinical Test Findings at the 12-Month Outcome Examination for Infants
Outcome No. (%) P
ValueOverall Total Dosage of Bevacizumab Injected Into Both
Eyes Prior to 12 mo, mg
≤0.1875 0.25-0.375 ≥0.50
Eyes, No. 46 19 13 14 NA
Ocular Alignment at Distance
Strabismus
Constant 3 (7) 2 (11) 1 (8) 0 (0)
NA
Intermittent 1 (2) 1 (5) 0 (0) 0 (0)
Orthotropic 33 (72) 15 (79) 8 (62) 10 (71)
Unable 9 (20) 1 (5) 4 (31) 4 (29)
Ocular Alignment at Near
Strabismus
Constant 5 (11) 3 (16) 2 (15) 0 (0)
NA
Intermittent 8 (17) 2 (11) 4 (31) 2 (17)
Orthotropic 33 (72) 14 (74) 7 (54) 12 (86)
Unable 0 0 0 0
Constant or intermittent at
distance or near, No. (%) [95%
CI]
13 (30) [17-45] 5 (26) [9-51] 6 (46) [19-75] 2 (14) [2-48]
.27
Manifest nystagmus, No. (%)
[95% CI]
7 (15) [6-29] 2 (11) [1-33] 1 (8) [0-36] 4 (29) [8-58]
.37
Amblyopia, No. (%) [95% CI] 3 (7) [1-18] 0 (0 [0-18] 2 (15) [2-45] 1 (8) [0-36] .25
Anisometropia
Refraction not done 1 [Reference] 0 0 1 [Reference]
0 D 19 (42) 10 (53) 6 (46) 3 (23)
NA>0-≤1.50 D 21 (47) 7 (37) 6 (46) 8 (62)
>1.50 D 5 (11) 2 (10) 1 (8) 2 (15)
Open in a separate window
Abbreviations: IQR, interquartile range; NA, not applicable.
The P values were reported for constant or intermittent alignment at distance or near. Where data are presented as
both a continuous and categorical outcome, a P value is only presented for the outcome as a continuous measure.
Number of infants treated initially with bevacizumab examined at the 12-month examination. Total dosage of
bevacizumab grouped into 3 groups.
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Since there is a limited number of outcomes, the P value is from a Fisher exact test without accounting for any
correlation between eyes for an association between the binary outcome and total dose as categorical factor.
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